|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ryan DP, Hong TS and Bardeesy N:
Pancreatic adenocarcinoma. N Engl J Med. 371:2140–2141. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Long J, Luo GP, Xiao ZW, Liu ZQ, Guo M,
Liu L, Liu C, Xu J, Gao YT, Zheng Y, et al: Cancer statistics:
Current diagnosis and treatment of pancreatic cancer in Shanghai,
China. Cancer Lett. 346:273–277. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wallace DR, Spandidos DA, Tsatsakis A,
Schweitzer A, Djordjevic V and Djordjevic AB: Potential interaction
of cadmium chloride with pancreatic mitochondria: Implications for
pancreatic cancer. Int J Mol Med. 44:145–156. 2019.PubMed/NCBI
|
|
5
|
Suzuki K, Takeuchi O, Suzuki Y and
Kitagawa Y: Mechanisms of metformin's anti tumor activity against
gemcitabine resistant pancreatic adenocarcinoma. Int J Oncol.
54:764–772. 2019.
|
|
6
|
Luo G, Liu C, Guo M, Long J, Liu Z, Xiao
Z, Jin K, Cheng H, Lu Y, Ni Q, et al: CA19-9-Low&Lewis(+)
pancreatic cancer: A unique subtype. Cancer Lett. 385:46–50. 2017.
View Article : Google Scholar
|
|
7
|
Robert M, Jarlier M, Gourgou S, Desseigne
F, Ychou M, Bouché O, Juzyna B, Conroy T and Bennouna J:
Retrospective analysis of CA19-9 decrease in patients with
metastatic pancreatic carcinoma treated with FOLFIRINOX or
gemcitabine in a randomized phase III study (ACCORD11/PRODIGE4).
Oncology. 93:367–376. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Humphris JL, Chang DK, Johns AL, Scarlett
CJ, Pajic M, Jones MD, Colvin EK, Nagrial A, Chin VT, Chantrill LA,
et al: NSW Pancreatic Cancer Network: The prognostic and predictive
value of serum CA19.9 in pancreatic cancer. Ann Oncol.
23:1713–1722. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Luo G, Fan Z, Cheng H, Jin K, Guo M, Lu Y,
Yang C, Fan K, Huang Q, Long J, et al: New observations on the
utility of CA19-9 as a biomarker in Lewis negative patients with
pancreatic cancer. Pancreatology. 18:971–976. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Guo M, Luo G, Lu R, Shi W, Cheng H, Lu Y,
Jin K, Yang C, Wang Z, Long J, et al: Distribution of Lewis and
Secretor polymorphisms and corresponding CA19-9 antigen expression
in a Chinese population. FEBS Open Bio. 7:1660–1671. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Luo G, Liu C, Guo M, Cheng H, Lu Y, Jin K,
Liu L, Long J, Xu J, Lu R, et al: Potential biomarkers in Lewis
negative patients with pancreatic cancer. Ann Surg. 265:800–805.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gao HF, Wang QY, Zhang K, Chen LY, Cheng
CS, Chen H, Meng ZQ, Zhou SM and Chen Z: Overexpressed
N-fucosylation on the cell surface driven by FUT3, 5, and 6
promotes cell motilities in metastatic pancreatic cancer cell
lines. Biochem Biophys Res Commun. 511:482–489. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Luo G, Guo M, Jin K, Liu Z, Liu C, Cheng
H, Lu Y, Long J, Liu L, Xu J, et al: Optimize CA19-9 in detecting
pancreatic cancer by Lewis and Secretor genotyping. Pancreatology.
16:1057–1062. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wiśniewski JR, Zougman A, Nagaraj N and
Mann M: Universal sample preparation method for proteome analysis.
Nat Methods. 6:359–362. 2009. View Article : Google Scholar
|
|
15
|
Luo G, Xiao Z, Long J, Liu Z, Liu L, Liu
C, Xu J, Ni Q and Yu X: CA125 is superior to CA19-9 in predicting
the resectability of pancreatic cancer. J Gastrointest Surg.
17:2092–2098. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tsai S, George B, Wittmann D, Ritch PS,
Krepline AN, Aldakkak M, Barnes CA, Christians KK, Dua K, Griffin
M, et al: Importance of normalization of CA19-9 levels following
neoadjuvant therapy in patients with localized pancreatic cancer.
Ann Surg. Oct 11–2018.Epub ahead of print. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Takada A, Ohmori K, Yoneda T, Tsuyuoka K,
Hasegawa A, Kiso M and Kannagi R: Contribution of carbohydrate
antigens sialyl Lewis A and sialyl Lewis X to adhesion of human
cancer cells to vascular endothelium. Cancer Res. 53:354–361.
1993.PubMed/NCBI
|
|
18
|
Engle DD, Tiriac H, Rivera KD, Pommier A,
Whalen S, Oni TE, Alagesan B, Lee EJ, Yao MA, Lucito MS, et al: The
glycan CA19-9 promotes pancreatitis and pancreatic cancer in mice.
Science. 364:1156–1162. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gebauer F, Wicklein D, Stübke K, Nehmann
N, Schmidt A, Salamon J, Peldschus K, Nentwich MF, Adam G,
Tolstonog G, et al: Selectin binding is essential for peritoneal
carcinomatosis in a xenograft model of human pancreatic
adenocarcinoma in pfp–/rag2– mice. Gut. 62:741–750. 2013.
View Article : Google Scholar
|
|
20
|
Hamada E, Taniguchi T, Baba S and Maekawa
M: Investigation of unexpected serum CA19-9 elevation in
Lewis-negative cancer patients. Ann Clin Biochem. 49:266–272. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Padró M, Cobler L, Garrido M and de Bolós
C: Down-regulation of FUT3 and FUT5 by shRNA alters Lewis antigens
expression and reduces the adhesion capacities of gastric cancer
cells. Biochim Biophys Acta. 1810:1141–1149. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Orntoft TF, Vestergaard EM, Holmes E,
Jakobsen JS, Grunnet N, Mortensen M, Johnson P, Bross P, Gregersen
N, Skorstengaard K, et al: Influence of Lewis
alpha1-3/4-L-fucos-yltransferase (FUT3) gene mutations on enzyme
activity, erythrocyte phenotyping, and circulating tumor marker
sialyl-Lewis a levels. J Biol Chem. 271:32260–32268. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Weston BW, Hiller KM, Mayben JP, Manousos
GA, Bendt KM, Liu R and Cusack JC Jr: Expression of human
alpha(1,3)fucosyltransferase antisense sequences inhibits
selectin-mediated adhesion and liver metastasis of colon carcinoma
cells. Cancer Res. 59:2127–2135. 1999.PubMed/NCBI
|
|
24
|
Fan K, Yang C, Fan Z, Huang Q, Zhang Y,
Cheng H, Jin K, Lu Y, Wang Z, Luo G, et al: MUC16 C
terminal-induced secretion of tumor-derived IL-6 contributes to
tumor-associated Treg enrichment in pancreatic cancer. Cancer Lett.
418:167–175. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Fleming ND, Cass I, Walsh CS, Karlan BY
and Li AJ: CA125 surveillance increases optimal resectability at
secondary cytoreductive surgery for recurrent epithelial ovarian
cancer. Gynecol Oncol. 121:249–252. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Akita K, Tanaka M, Tanida S, Mori Y, Toda
M and Nakada H: CA125/MUC16 interacts with Src family kinases, and
over-expression of its C-terminal fragment in human epithelial
cancer cells reduces cell-cell adhesion. Eur J Cell Biol.
92:257–263. 2013. View Article : Google Scholar : PubMed/NCBI
|
